WillItSurvive
Pharma and healthcare groups · China

Junshi Biosciences

junshipharma.com ↗

Chinese biopharma selling toripalimab, a PD-1 cancer drug, in China and the US as LOQTORZI.

Losing its protection
Assessed 26 July 2026 · Evidence as of 26 July 2026
The structural protection is eroding.
On the recordSince 26 July 2026 · Checkable from around Q1 2027 · Every call on the record Checkpoint: NMPA decision on toripalimab's perioperative stage II-III NSCLC supplemental application
The call

Junshi holds real regulatory ground with toripalimab, but domestic price competition and a likely capital raise keep the picture unsettled.

Junshi Biosciences makes toripalimab, a cancer immunotherapy approved and reimbursed in China, plus they own factories certified to make it. Copying this is hard because the company already has government approvals, insurance coverage in three disease areas, and manufacturing licenses that took years to earn, and AI cannot fast-track any of that. But Junshi is bleeding money while five other Chinese competitors and giants like Merck are already selling similar drugs at rock-bottom prices in China, so the company might need to raise cash again soon (diluting shareholders) or prove their newer drugs can make real money before toripalimab becomes worthless. The real question is whether Junshi stops losing money and grows revenue from new medicines before price competition destroys the old one.

Why
01
AI pressure: None apparent. AI protein tools can speed drug discovery industry-wide but cannot win NMPA/FDA approval or run CGMP manufacturing, so it does not directly threaten Junshi. Could AI do the core job? Unlikely.
02
Bigger players: Innovent Biologics (sintilimab), Akeso (ivonescimab), BeiGene, Hengrui, and Henlius. Rival PD-1 drugs are already on the market and NRDL-listed, squeezing prices even as Junshi's own sales still grow. Could a giant copy it? Probably.
03
What protects it. Toripalimab holds NMPA and FDA approval plus sole NRDL reimbursement for melanoma, kidney cancer, and triple-negative breast cancer.
What would change this call
NMPA decision on toripalimab perioperative NSCLC sNDA, expected within ~6 months of July 2026. Would show whether Junshi can widen its label lead over domestic PD-1 rivals.
Whether Junshi announces another equity or convertible raise in the next 6-12 months. Would show if cash strain forces dilution despite narrowing losses.
Data readout comparing JS207 (PD-1/VEGF bispecific) against Akeso's ivonescimab. Would show whether Junshi's pipeline can differentiate from Akeso rather than just match it.
Key numbers
  • FY2025 revenue RMB2,498M, up 28% year over year (2026-03-13)
  • Net loss narrowed 34% to RMB841M in FY2025 (2026-03-13)
  • Toripalimab now covers 12 approved indications in China (2026-07-21)
Named risks
  • Continued net losses (RMB841M FY2025) may force another dilutive capital raise within 6-12 months. Severity: high
  • NRDL price erosion in commoditized domestic PD-1 market from Innovent, Akeso, BeiGene, Hengrui, Henlius. Severity: high
  • Akeso's ivonescimab bispecific is ahead of Junshi's JS207 in clinical development and differentiation. Severity: medium
  • Pre-IPO shareholder Shanghai Tanying executing share selldown through Q1 2026 may pressure stock price. Severity: medium
  • Status of Coherus partnership for US LOQTORZI commercialization unverified, materially affects ex-China revenue. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Akeso Inc.losing toIvonescimab beat Keytruda head to head in NSCLC trial reported Sep 2024, ~12-18 months ahead of Junshi's JS207
Shanghai Henlius Biotechlosing toHenlius has larger headcount (~3.76k) and larger market cap (~HKD 34.7bn) than Junshi as of mid-2026
Innovent BiologicscontestingSintilimab and Junshi's toripalimab both compete in China's NRDL-listed PD-1 category as of 2026
BeiGenecontestingDomestic PD-1 rival with NRDL access shipping alongside Junshi's toripalimab through 2026
Hengrui PharmaceuticalscontestingDomestic PD-1 peer pressuring pricing in China's reimbursement market as of 2026
Merck (Keytruda) and BMS (Opdivo)gaining onGlobal PD-1 franchise leaders structurally barred from China's price point but dominate ex-China markets
Questions people ask
Is Junshi Biosciences profitable in 2026?
Not yet. Junshi's net loss attributable to shareholders narrowed 34% year over year to RMB841 million in FY2025, even as total revenue rose about 28% to RMB2,498 million, according to its March 2026 full year results announcement.
What is Junshi Biosciences best known for?
Junshi developed toripalimab, the first domestically developed Chinese anti-PD-1 antibody approved for marketing in China, sold as TUOYI domestically and LOQTORZI in the US, where the FDA approved it in October 2023.
Who are Junshi Biosciences' biggest competitors?
Domestically, Junshi competes with Innovent Biologics, Akeso, BeiGene, Hengrui Pharmaceuticals, and Shanghai Henlius Biotech in China's crowded PD-1 market. Globally, Merck's Keytruda and BMS's Opdivo dominate the PD-1 category outside China.
Could AI replace Junshi Biosciences?
No. Junshi's value rests on NMPA and FDA drug approvals, NRDL reimbursement exclusivity for melanoma, RCC and TNBC, and CGMP-certified manufacturing at Suzhou Union, all regulation gated barriers AI tools like AlphaFold cannot replicate or bypass.
Does Junshi Biosciences need to raise more capital?
Junshi raised roughly HK$1,026 million (about $132 million) in a June 2025 H-share placing at HK$25.35 per share, and continued cash burn against a net loss of RMB841 million in FY2025 suggests another dilutive raise is plausible within 6 to 12 months.
Is Junshi Biosciences' stock volatile?
Yes. As of July 2026, Junshi's 52 week trading range on the Hong Kong exchange was roughly HK$15.25 to HK$38.64, a spread of about 2.5 times, with market capitalization around HKD 36.6 billion (about $4.7 billion).
Timeline
  • 2026-07-21NMPA accepts supplemental application expanding toripalimab perioperative NSCLC indication to stage II-III
  • 2026-07-01Junshi licenses roconkibart Greater China rights to Fosun Wanbang
  • 2026-03-13Junshi reports FY2025 revenue RMB2,498M, net loss RMB841M, narrowed 34% YoY
  • 2026-02-24Strategic collaboration announced with Antengene combining JS207 and ATG-037
  • 2025-12NMPA accepts NDA for roconkibart (JS005) for plaque psoriasis
  • 2025-11JS001sc subcutaneous toripalimab meets Phase 3 primary endpoints in first-line NSQ-NSCLC
  • 2025-08-26H1 2025 results: revenue RMB1,168M, up 49% YoY
  • 2025-06Suzhou Union manufacturing subsidiary passes unannounced FDA CGMP inspection
  • 2025-06H-share placing of 41M shares at HK$25.35 raises approximately HK$1,026M
  • 2023-10FDA approves toripalimab in the US as LOQTORZI
Revision history
26 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Community Health SystemsViatrisAccendra Health
More in Pharma and healthcare groups →
Sources